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Abstract
Background: Genetic testing for risk of hereditary cancer can help patients to make important decisions about
prevention or early detection. US and UK studies show that people from ethnic minority groups are less likely to
receive genetic testing. It is important to understand various groups’ awareness of genetic testing and its acceptability to
avoid further disparities in health care. This review aims to identify and detail awareness, knowledge, perceptions, and
attitudes towards genetic counselling/testing for cancer risk prediction in ethnic minority groups.
Methods: A search was carried out in PsycInfo, CINAHL, Embase and MEDLINE. Search terms referred to ethnicity, genetic
testing/counselling, cancer, awareness, knowledge, attitudes, and perceptions. Quantitative and qualitative studies, written
in English, and published between 2000 and 2015, were included.
Results: Forty-one studies were selected for review: 39 from the US, and two from Australia. Results revealed low
awareness and knowledge of genetic counselling/testing for cancer susceptibility amongst ethnic minority groups
including African Americans, Asian Americans, and Hispanics. Attitudes towards genetic testing were generally positive;
perceived benefits included positive implications for personal health and being able to inform family. However, negative
attitudes were also evident, particularly the anticipated emotional impact of test results, and concerns about
confidentiality, stigma, and discrimination. Chinese Australian groups were less studied, but of interest was a
finding from qualitative research indicating that different views of who close family members are could impact on
reported family history of cancer, which could in turn impact a risk assessment.
Conclusion: Interventions are needed to increase awareness and knowledge of genetic testing for cancer risk and to
reduce the perceived stigma and taboo surrounding the topic of cancer in ethnic minority groups. More detailed
research is needed in countries other than the US and across a broader spectrum of ethnic minority groups
to develop effective culturally sensitive approaches for cancer prevention.
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Background
Several types of cancer have been found to be associated
with hereditary gene mutations [1, 2]. Specifically, muta-
tions in the BRCA1 and BRCA2 genes are known to be
linked to breast, ovarian [3, 4], and prostate cancer [5].
Over the past 20 years, the scientific understanding of
cancer related genetics has greatly improved. Within
several European countries and the US, patients diag-
nosed with a potentially hereditary cancer or with a
strong family history can receive genetic counselling and
testing to establish whether they have an inherited can-
cer gene mutation. Knowledge about personal cancer
risk can help currently healthy individuals to make
health care decisions, such as whether to attend regular
screening or opt for surgery, in order to help reduce the
risk of developing cancer [6].
Public attitudes towards genetic testing for the risk of
diseases, including cancer, have been found to be gener-
ally positive [7–9]. In a US study, 97% of participants in-
dicated that they were at least somewhat interested in
the topic of genetic testing and the majority had positive
attitudes about genetic research and approved of the use
of genetic testing in the detection of diseases [9].
Positive attitudes towards genetic testing are also re-
ported in a Dutch survey study that found that 64%
of participants believed genetic testing would help
people to live longer [8]. However, there are also con-
cerns amongst the general public that genetic test re-
sults could be used to discriminate against those with
a genetic predisposition for illness [9] and that gen-
etic testing could result in people being labelled as
having “good” or “bad” genes [8].
The incidence and burden of cancer varies between
ethnic groups. In the UK, incidence of breast cancer is
higher amongst White women compared to all other
ethnic groups [10], but Black men have higher rates of
prostate cancer than White men [11]. Similarly, in the
US overall cancer incidence and mortality has been
found to be highest in Black men compared to other
ethnic groups, and whilst Black women have a lower in-
cidence of breast cancer than White women they have a
worse mortality rate [12]. In the US Hispanics are re-
ported to have lower incidence and mortality rates of
cancer than White Americans [13], and evidence sug-
gests that whilst Asian Americans also tend to have
lower cancer rates than Whites, increasing incidence
rates have been detected between 1990 and 2008 for
breast, colorectal, and uterine cancer amongst several
subgroups of Asian American women [14].
Despite the potential health benefits of cancer suscep-
tibility testing, ethnic minority groups have been found
to be underserved by genetic services and underrepre-
sented in research in Europe and the US [15–18]. In a
UK study, only 3% of patients referred to 22 regional
genetics services were from an ethnic minority group
[19]. Armstrong et al. [20] also found that women
pursuing BRCA1/2 genetic testing in a US study were
significantly more likely to be White, and Levy et al. [21]
report that significantly fewer Black and Hispanic
women with a new diagnosis of breast cancer and at risk
of carrying a BRCA gene mutation had genetic testing.
A previously published review investigating what may
hinder African, White Irish, and South Asian ethnic mi-
nority groups’ access to cancer genetic services found
potential barriers included low awareness and knowledge
of genetic testing and available services, language bar-
riers, stigma associated with being at risk, fatalistic views
of cancer, anticipation of negative emotions, uncertainty
about the information provided, and mistrust of how
data would be used [22]. The current review aims to in-
vestigate factors that might act as barriers or facilitators
to the uptake of genetic testing across diverse ethnic mi-
nority groups. The review fills a critical knowledge gap
by focusing on awareness, knowledge, perceptions, and
attitudes towards genetic testing for cancer susceptibil-
ity, and reasoning for and against testing by people from
Black and ethnic minority backgrounds.
Methods
The systematic review followed PRISMA guidelines and
an a priori published protocol (https://www.crd.york.
ac.uk/PROSPERO/ CRD42016033485).
Eligibility
The review includes primary studies that aimed specifically
to investigate ethnic minority groups’ awareness, know-
ledge, perceptions, and attitudes, or provide information
on participants’ reasons for/against interest, intentions or
actual uptake of genetic testing/counselling for personal
cancer risk. Studies with a focus on genetic testing or gen-
etic counselling were included as currently these services
often go hand-in-hand and we wanted to see if there were
important attitudes affecting uptake. We included quanti-
tative and qualitative studies conducted in Europe, the US
or Australia, and published in English in a peer reviewed
journal from the year 2000 onwards.
Research that investigated awareness/attitudes/percep-
tions of direct-to-consumer genetic testing, or that only
investigated participants’ perceptions of cancer or their
experience of receiving genetic information were excluded
from the review. Articles that evaluated recruitment
methods, or interventions to raise awareness/knowledge
of genetic testing amongst ethnic minority groups were
also excluded. Studies focusing mainly on Ashkenazi
Jewish participants were not included as this group is
known to have an increased risk of carrying BRCA1/2
gene mutations which might uniquely influence their
knowledge/interest/attitudes to genetic testing. Ashkenazi
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Jewish women also have a high level of acceptance of gen-
etic testing [23, 24]. Unpublished research was not sought
for this review.
Study search
Four databases were searched in December 2015: Psy-
cInfo (OVID interface), CINAHL (EBSCO interface),
Embase (OVID interface) and MEDLINE (OVID inter-
face). The search terms included a combination of the-
saurus (MeSH) terms and keywords such as: ‘ethnic’ or
‘minorit*’ or ‘African’ or ‘Asian’, combined with ‘know*’ or
‘aware*‘or ‘attitude*’ or ‘perception*’ and ‘cancer’ and ‘gen-
etic testing’ or ‘genetic counselling’. [See Additional file 1
for full lists of search terms.]
Study selection
Figure 1 presents the article selection process. Study ar-
ticles were independently selected by two researchers
[KH & MF]. Articles were initially identified by the titles
and abstracts and those which appeared eligible were
reviewed in full. A reference list search was also con-
ducted to identify additional articles. Any disagreements
or uncertainties on the inclusion of studies were brought
to a third researcher [AL] to make a final decision.
Data extraction and analysis
A data extraction tool was designed to gather relevant
information on the study design, methods, and results
on awareness, knowledge, attitudes, and perceptions re-
lating to genetic testing/counselling for cancer risk.
A thematic synthesis of the qualitative research was car-
ried out in line with recommendations by Thomas and
Harden [25]. The synthesis involved extracting and analys-
ing each article’s results section, including direct quotes.
An iterative process of re-reading and coding the text was
used, and a coding manual was produced based on the
themes identified. Once coding was completed a second
researcher [MF] independently analysed 20% of the quali-
tative data using the coding manual. The analysis was
organised using the software package NVivo (version10).
Quality assessment
The quality of each study was assessed using tried and
tested tools designed by Kmet et al. [26] for quantitative
and qualitative research. The assessment tool criteria in-
cluded an assessment of the description of the study ob-
jective, design, methods, data analysis, and conclusions.
Criteria are scored using a 3-point Likert scale: 0 (criteria
not fulfilled); 1(partial fulfilment); 2 (criteria fulfilled). A
final score is calculated by adding all relevant criteria scores
and dividing by the total possible score for each study. The
included articles were independently quality assessed by
two researchers [KH & MF]. When disagreements arose
they were discussed until consensus was reached.
Results
For the purpose of the review we have standardised the
terms used to refer to the groups included, see Table 1
for a key and frequencies of groups included across the
studies. Table 2 summarises the 31 quantitative studies
and the results on ethnic minority groups’ awareness,
knowledge, attitudes, and perceptions in regards to gen-
etic counselling (n = 2), genetic testing (n = 27), or both
(n = 2) for cancer risk. Measures used in the studies
were often non validated study specific instruments and
due to their heterogeneity across different ethnic groups
and in reference to different cancers a meta-analysis of the
results was not possible [see Additional file 2 for a list of
the measures used]. Table 3 presents a summary of the 10
qualitative and mixed methods studies, noting themes as
originally identified. Of these 10 qualitative studies, 5 in-
volved interviews, 4 involved focus groups and 1 used
both focus groups and in-depth interviews. The tables
have been arranged by ethnicity and cancer type.
A total of 82,432 individuals from African American,
Hispanic, Asian American, White, and Chinese Austra-
lian ethnic groups took part in the 41 studies reviewed.
Thirty-nine of the forty-one studies were conducted in
the US and two were conducted in Australia. Breast and
ovarian cancer or BRCA genetic testing were most fre-
quently referred to within the reviewed research, twelve
referred to a number of cancers or cancer in general,
three referred to prostate cancer, two to colon/colorectal
cancer, and one to lung cancer.
Quantitative studies
Awareness
Awareness was measured in two ways across 15 studies;
either a dichotomous Yes/No question [27–35] or a
measure asking participants how much they had heard/
read about genetic testing [36–41]. Figure 2 presents the
percentage of participants who indicated awareness or
having heard/read a fair amount/a lot about genetic test-
ing for cancer risk by study and ethnic group. Within
general population samples of Hispanics, awareness of
genetic testing for cancer risk ranged from 7.7% of
Spanish only speaking Hispanics [28] to 27.9% of internet
users [30]. Across two samples of Hispanics with a high
risk of cancer due to family history or a personal experi-
ence of cancer, 46.7% [38] and 47.1% [41] were aware of
genetic counselling for cancer risk in general; awareness
of genetic counselling for colon, breast, and ovarian can-
cer varied. Whilst Gammon et al. [27] found 43.1% of a
Hispanic sample were aware of BRCA1/2 testing, this
sample included only high cancer risk participants of
whom several had already had genetic testing.
Amongst African Americans, awareness of genetic
testing for cancer risk ranged from 29% [30] to 54% in
general population samples [35]. Awareness of the
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BRCA1/2 gene and mutation testing appears to be par-
ticularly low, one study [35] reported that only 12% were
aware and another [33] reported that 25% of African
American participants were aware. Two studies reported
that around 25% of Asian Americans were aware of gen-
etic testing for cancer risk [31, 32].
Five studies reported that awareness significantly differed
by ethnicity, with more White participants being aware of
genetic testing for cancer risk than Hispanics, African
Americans, and Asian Americans [29, 30, 32, 33, 40]. Vada-
parampil et al. [34] also reported that whilst 20% of their
Hispanic sample were aware of genetic testing for cancer
risk, awareness varied by ethnic subgroups.
Only one study assessed whether awareness was asso-
ciated with intentions to have genetic counselling, and
found no significant association [41].
Knowledge
Eight of the included studies measured knowledge of
hereditary cancer genetics within samples at an in-
creased risk for cancer based on family history and in-
cluding individuals with a personal cancer diagnosis
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N = 89
Article identified 
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Article identified 
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N = 462
Article identified 
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N = 813
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Duplicates removed
N = 526
Selected for further 
assessment/ discussion
N = 71
Selection for inclusion
N = 40
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from reference list 
search
N = 1
Articles excluded
N = 889
Total to be reviewed for 
inclusion by title/ abstract
N = 960
Articles excluded N = 31
13 did not provide information 
on awareness, knowledge,
attitudes and perceptions.
10 did not specifically aim to 
investigate an ethnic minority 
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4 review papers/meeting 
abstracts.
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Fig. 1 Study inclusion flow diagram. The flow diagram presents the processes of inclusion and exclusion to identify the final sample of articles to
be included in the review and reasons for excluding articles
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[41–48]. Figure 3 presents the average percentage of cor-
rectly answered knowledge questions across the studies.
Findings suggest that knowledge was varied but limited
amongst African Americans, with between 30% and 70% of
questions answered correctly on average across five studies
[42–46]. Two studies suggested that Hispanic participants
also had limited knowledge, with scores of approximately 5
out of 11 for hereditary breast cancer knowledge [47, 48],
although a high average score of 43.8 out of 55 was
observed for genetic counselling knowledge in a third [41].
Only Donovan and Tucker [42] found a significant
difference between African American and White partici-
pants’ scores on cancer genetics knowledge, indicating
lower knowledge in the African American group. How-
ever the overall difference between scores was small,
with a mean score of 7.7 out of 14 for Whites and 7.0
for African American.
High cancer genetics knowledge was found to be a sig-
nificant predictor of genetic testing uptake in one study
with African Americans [44]. In another study, those who
participated in genetic counselling and testing had signifi-
cantly higher scores for knowledge of cancer genetics than
those who accepted neither, however cancer genetics
knowledge did not reach significance as a predictor of
genetic testing uptake [45]. Three other studies found no
associations between cancer genetics knowledge and inter-
est in or intentions to have genetic testing [41–43].
Attitudes and perceptions
Several different measures of attitudes/beliefs/percep-
tions regarding genetic testing or counselling were used,
although similar items were used across these. Some
studies reported attitude scores and others reported the
number or percentage of participants who agreed with each
statement. Ten studies reported that African American
and Hispanic participants highly endorsed statements
about the benefits of genetic counselling/testing for cancer
risk, whilst endorsing limitations to a lesser extent
[36–38, 41, 42, 45, 47, 49–51]. The results indicate that
overall participants had positive attitudes and perceived
several benefits of genetic testing.
Highly endorsed benefits of genetic counselling/testing
for cancer risk included: to help make decisions on (en-
hanced) screening (endorsed by 81–100%) [36, 42, 43,
45, 49, 50]; to motivate self-examination (endorsed by
90–92%)[43, 45, 49]; receipt of information for family/
being able to help family and children (endorsed by 38–
99%) [27, 36, 38, 41, 43, 45, 47, 49, 52]; to reduce concern
about cancer (endorsed by 60–90%) [38, 41, 43, 45, 49]; to
reduce uncertainty (endorsed by 68–100%) [42, 43, 50]; to
provide a sense of personal control (endorsed by 67–79%)
[37, 43, 45, 49]; to help plan for the future (endorsed by
66%) [36, 52]. More variation was seen in attitudes to-
wards benefits such as: to help make important life de-
cisions (endorsed by 21–88%) [36, 41, 43, 45, 49, 50]; to
provide reassurance (endorsed by 42–80% of partici-
pants) [38, 50, 52, 53]; to help with cancer prevention
(endorsed by 31–88%) [27, 33, 50]; and to help make
decisions about preventative surgery (endorsed by 44–
77%) [41, 43, 45, 50]. Similarly, Kinney et al. [44] report
that, when asked for reasons why they enrolled for gen-
etic testing, participants cited family/personal motives
(62%), information (28%), and society (9%).
Some of the most frequently endorsed limitations or
barriers to genetic testing/counselling included: antici-
pated increased worry about offspring/relatives if test re-
sult is positive (endorsed by 53–95%) [38, 41, 43, 45, 49];
anticipated personal emotional reaction if test result
is positive e.g. worry, fear, anger (endorsed 31–75%)
[27, 36–38, 43, 45, 49, 52, 53]; concern about family’s
reaction or impact on family (endorsed by 27–52%)
[36, 49, 50, 52]; concerns about confidentiality (en-
dorsed by 12–72%) [40, 42, 45, 49, 50]; concern about
jeopardising/losing insurance (endorsed by 11–58%)
[33, 36, 38, 41, 43, 45, 47, 49, 50]; cost (endorsed by
32–40%) [27, 47]; and feeling unable to handle the
Table 1 Key for ethnicity terms
Term used
throughout
Includes N Studies
African American African American 23 30, 31, 32, 33, 37, 40,
42, 43, 44, 45, 46, 50,
51, 52, 53, 54, 55, 56,
57, 59, 60, 63, 65
Black 3 29, 35, 58
African American & West
Indian
1 49
27
Hispanic Hispanic 9 28, 30, 29, 32, 34, 36,
48, 53, 67
Latina/o 9 27, 31, 38, 39, 40, 41,
61, 63, 66
Puerto Rican 1 47
Mexican/Mexican-
American, Cuban-American
Dominican (Republic)
Central or South American
19
Asian American Asian American 4 31, 32, 53, 63,
White White 5 30, 31, 32, 53, 57,
Non-Hispanic White 1 29
Non-Latina/o White 2 27,63
Caucasian 4 33, 40, 42, 65
12
Other Other 2 29, 53
Chinese
Australian
Chinese Australian 2 62, 64
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test emotionally (endorsed by 3–40%) [40, 42, 49, 50]. Re-
ported reasons for a lack of interest/intention to pursue
testing included cost, time, worry that others would find
out, belief the results could be wrong, worry about in-
creased risk, concern about discomfort, concern about
discrimination, not wanting blood taken, logistical rea-
sons, personal reasons, and having heard negative experi-
ences of others who had undergone testing [44, 54, 55].
In studies comparing ethnic groups, results suggest
that those from ethnic minority groups may hold less
positive views or have greater concerns about genetic
counselling/testing compared to White participants. Pe-
ters et al. [33] found that compared to White partici-
pants, African Americans were less likely to endorse
health benefits of genetic testing and were more likely to
believe that the government would use test results to
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Cancer genetics, GT acceptors
Weinrich et al. (2007)
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label groups as inferior, however there were no other
significant differences between the groups on attitudes
towards insurance and job discrimination due to genetic
test results. Sussner et al. [56] also reported that foreign
born African American participants anticipated a more
negative emotional reaction to genetic testing than those
born in the US. Thompson et al. [40] found that African
Americans and Latinas had significantly higher medical
mistrust than Whites, and were more likely to believe
that genetic test results would be used to show that their
ethnic group is not as good as others, or to interfere
with the natural order of things. Latinas with lower levels
of acculturation and heightened medical mistrust also
cited more barriers to genetic testing [39]. However, whilst
Armstrong et al. [57] found that significantly more African
Americans had high healthcare mistrust, there was no sig-
nificant difference between African American and White
participants’ willingness to undergo cancer risk genetic
testing across several hypothetical scenarios.
Attitudes and perceptions were associated with uptake,
interest, or intentions to have genetic testing in ten stud-
ies. Thompson et al. [45] reported that those who
attended genetic counselling/testing perceived signifi-
cantly fewer barriers and had more intrusive thoughts of
breast cancer than those who did not. Similarly, Donovan
and Tucker [42] reported that being at least somewhat in-
terested in genetic testing was associated with more posi-
tive beliefs. Seven studies found that perceived high risk of
cancer or of being a cancer gene mutation carrier was as-
sociated with acceptance of genetic testing or interest/in-
tentions to test [41–44, 50, 53, 58]; however, one study
reported that perceived cancer susceptibility was nega-
tively associated with intentions [54]. Whilst Hughes et al.
[59] found higher fatalistic beliefs about cancer in genetic
test accepters than decliners, Myers et al. [54] indicated a
negative association between fatalism about prostate can-
cer prevention and intentions to receive prostate cancer
testing to find out about personal risk. Other attitudes and
perceptions positively associated with genetic testing
uptake or interest/intentions included the absence of the
belief that testing leads to discrimination, reassurance
from testing [53], belief in efficacy of screening [54], per-
ceiving that it is good to know future risk, and believing in
control through knowledge [37].
Qualitative studies
The 10 qualitative studies included 31 Chinese Austra-
lians, 17 Asian Americans, 120 African Americans, and
163 Hispanics. The majority of participants were female
and were at high risk of cancer based on family history
or had a diagnosis of cancer, one study used a sample of
the general population [35]. The thematic synthesis of
the qualitative studies identified five broad themes: in-
formation deficits; cancer related anxiety; positive and
negative attitudes and perceptions; family; and service
provision and access.
Information deficits
Although some studies indicated that participants had
good awareness and knowledge of hereditary cancer and
the involvement of genetics, these participants tended to
be those who had experienced cancer themselves or in a
close family member [60, 61], or had previously attended
genetic counselling [62, 63].
“Genes have a big part in us having cancer. My family
has a higher chance of getting cancer compared to
other families as many of our family members had
cancer.”
Chinese Australian, Eisenbruch et al. [62]
Several studies including Chinese Australian, Hispanic,
and African American samples reported that the majority
of participants had low awareness and knowledge about
the importance of genetics in cancer, BRCA, and genetic
testing [52, 60, 61, 63–67]. Some confusion on the differ-
ence between genetic counselling and genetic testing was
identified [61, 65]. Generational differences in awareness,
knowledge, and beliefs were observed in studies with His-
panic and Chinese Australian samples, indicating that
older generations were less aware and perhaps less open to
genetic testing for cancer risk [61–64]. Some Chinese
Australian participants reported that older generations and
those with traditional beliefs would not accept that mu-
tated genes can be passed through generations, attributing
the development of illness instead to bad luck or past bad
deeds [62, 64]. The lack of understanding about hereditary
cancer and unfamiliarity with genetic testing could act as a
barrier to testing. Participants across several studies
expressed a need for interventions, campaigns, and the
provision of information to increase awareness and know-
ledge of cancer and genetic testing [35, 52, 60, 61, 65].
“Nobody knows it [genetic testing]. They are so far
away [from Western medicine]. The mammogram is
coming out but this is the first time I heard about the
gene test.”
Asian American female, Glenn et al. [63]
“Black people aren’t into that yet. We need to know
more about it so it will not seem so farfetched.”
African American female, Matthews et al. [52]
Closely linked to participants’ low awareness and know-
ledge of cancer and genetic testing were the misconceptions
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held, including believing that genetic counselling prevents
cancer [65], stress causes cancer [52, 63], cancer is conta-
gious [62], injuries cause cancer [67], and focusing or
worrying about cancer causes it to develop [52, 62, 64]. It is
highlighted that some of these beliefs may make people less
willing to discuss cancer or attend cancer services.
“I have heard that if you hit your breasts, it could
cause cancer—I saw a woman who got cancer after
being hit with a bottle on her breast. My mother hit
her stomach and then she got cancer in her uterus.
The underwires in bras are not good and they harm
your breast tissue and cause cancer. I take them out.”
Hispanic female, Vadaparampil et al. [67]
Cancer related anxiety
Four studies found that African American and Hispanic
participants had fatalistic views of cancer, which they per-
ceived to be an illness that cannot be cured and is associ-
ated with death [52, 61, 65, 66]. Across all the included
ethnic groups participants associated emotions such as
worry, anxiety, and fear with cancer and genetic testing
[35, 52, 60, 61, 63–67]. Participants expressed that fear of
cancer and knowing their cancer risk was a deterrent to
genetic testing [35, 52, 60, 61, 63, 65–67]. Participants an-
ticipated experiencing anxiety whilst undergoing genetic
counselling/testing [52, 64] and worried about the poten-
tial emotional impact that a positive test result would have
on them [52, 67]. Some Hispanics reported that at times
embarrassment prevented them from seeking medical
help and attending cancer screening [63, 66]. Sheppard et
al. [60] also found that women were fearful of making de-
cisions about managing cancer risk after testing.
“… I think it will be harder for them to find out that
they have a gene or a mutation that may cause...their
body to develop cancer...in the future, and so I think
for a lot of people just knowing that they have the
mutation will be a lot more of anxiety source than
actually helpful…”
Hispanic, Kinney et al. [66]
However, within a Hispanic community, Sussner et al.
[61] found that younger generations were less fatalistic
about cancer and were more enthusiastic towards gen-
etic counselling.
“But now the word cancer is different from before…
before people were ashamed, now they believe they
will beat it, it was once a taboo.”
Hispanic female, Sussner et al. [61]
Positive and negative attitudes and perceptions
Interest in and positive attitudes towards genetic testing
for cancer susceptibility were identified [60, 63, 66]. Per-
sonal health benefits, such as cancer prevention, early
detection, and risk management, were highlighted as
main benefits of genetic counselling/testing by African
American, Hispanic, and Asian American participants
[35, 52, 63, 65, 66]. Some participants felt that genetic
testing would help to motivate them to be proactive to-
wards their health and take action by making positive
behavioural changes [35, 65] and others considered the
knowledge gained from genetic testing to be empower-
ing [61, 65].
Benefits of genetic testing included “the opportunity
for early detection, instead of waiting until the cancer
develops.”
African American female, Adams et al. [35]
Some African American and Hispanic participants dis-
cussed their spirituality and God, this was not presented
as a barrier to genetic testing but as a way of seeking
guidance and coping [60, 61, 67]. Some participants felt
that their spirituality was a motivator for finding out
about their cancer risk [65].
“I do believe that everything is in God’s hands,
regardless. But, I don’t think that my spiritual beliefs
would prevent me from going. If anything, they would
motivate me to go…”
African American female, Ford et al. [65]
Several negative attitudes and perceptions were held
by participants in relation to cancer and genetic testing.
Discussing illnesses such as cancer was described to be
taboo by Chinese Australian, African American, and
Hispanic participants [61, 62, 64, 66]. Participants ex-
plained that in their culture there is secrecy around can-
cer and individuals might not tell family if they had it
[64, 66]. This taboo is closely linked to the perceived
stigma of having an illness, feeling shame and not wanting
to be treated differently. Fear of discrimination by em-
ployers and insurers, and stigma was discussed across sev-
eral studies and highlighted as a deterrent to testing [35,
60, 61, 63, 65, 66]. Among Asian American and Chinese
Australian participants, there were also concerns that
receiving a positive genetic test result would create
stigma that they have “bad genes”, which could impact
on marriage prospects [63, 64].
“The stigma [would stop me from getting tested]
because you always have a concern that somewhere
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this information is gonna reside on a computer
somewhere; it may prevent you from getting
employment, future insurance, or any number of
things so that’s [my] concern. That is one thing that
has stopped me from going ahead with testing.”
African American female, Sheppard et al. [61]
Five of the eight qualitative studies conducted in the US
reported that participants, particularly African Americans,
discussed mistrust and disillusionment in the health care
system [35, 52, 61, 63, 65]. Participants expressed concerns
that their genetic data would be misused [63], that they
would be experimented on [52], and that tests were of-
fered to make money rather than out of necessity [52,
61]. Medical mistrust among some African Americans
was reported to stem from negative events in history
[52] and the “Tuskegee effect” relating to the mis-
treatment of African American men in the Tuskegee
Syphilis study [35]. Concerns regarding confidentiality,
what would happen with genetic test results after
testing, and concerns about private information being
discovered by others without the donor’s permission
were also highlighted as important issues [52, 61, 65].
“…I felt in the past that doctors have sent me for
tests just to get money. I feel that I was put through
something…really bad, going you know, put fear in
me for something…just so the doctor could put the
claim in and I would never trust. It was terrible…”
Hispanic female, Sussner et al. [61]
“One of my girlfriends who is so narrow-minded …
would say ‘I wouldn’t let those people experiment
[referring to genetic testing] on me’ …. Some of my
other friends, who are not as narrowminded would
think, ‘It’s best to find out all you can’… ‘Go for all
the tests you can’ ”
African American female, Glenn et al. [63]
Only one study, involving Asian American partici-
pants, suggested that a cultural mismatch exists between
genetic testing and their culture’s traditional medicine
[63]. However, scepticism of genetic testing was identi-
fied amongst Hispanic participants who were unsure of
the need for genetic testing and screening without hav-
ing symptoms [66], and others who felt there was no
point in knowing [67]. Some African Americans were
unsure of the test accuracy or reliability for their ethnic
group [35, 52]. Ford et al. [65] also reported that African
American women who did not attend genetic counsel-
ling perceived few benefits.
Family
The theme of Family was raised in discussion by many
participants and was described as both a motivator and
a barrier to testing. Two studies reported that Hispanics
identified a culture of prioritising family needs over their
own, resulting in a lack of time to attend health appoint-
ments [61, 63] and therefore a potential barrier to at-
tending genetic counselling or testing.
“The woman is meant to do everything, take care of
the house, take care of this, take care of that, so health
does go on the background…That’s how we were
raised. You last, everybody else first”
Hispanic female, Sussner et al. [61]
However, helping others in society [60, 63] and family
[35, 52, 60, 61, 63, 66] was cited as an important benefit
and motivator for genetic testing across most groups.
Some Hispanic participants also felt it was important
that they act as role models by making health more of a
priority and encouraging older women to attend genetic
counselling [61].
“I was the first one diagnosed with breast cancer in my
family, so I would be concerned about it for their sake
to find out what was going on…so that’s what would
motivate me, family.”
African American female, Sheppard et al. [60]
Only two studies referred to family support in relation
to genetic testing [61, 65]. Ford et al. [65] reported that
some African American women felt they lacked family
support to attend genetic counselling for cancer risk due
to the potential negative impact of finding out they were
high risk. Sussner et al. [61] reported that Hispanic par-
ticipants felt family support would motivate them to at-
tend genetic counselling. Both groups acknowledged
that the decision was ultimately theirs; therefore, a lack
of family support might not prevent individuals from
having genetic counselling or testing.
“[Family] wouldn’t keep me from going. If I wanted to
go, I would go”
African American female, Ford et al. [65]
A further issue specific to some Chinese Australians was
their understanding or definition of ‘close relatives’ [62, 64].
These studies highlighted that, due to the importance
placed on the paternal line, maternal family members might
not always be considered ‘close relatives.’ Furthermore,
when female relatives previously considered close relatives
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marry into other families, they may no longer be considered
as such. Some indicated that relatives would be considered
‘close’ depending on how much they interacted with them
rather than by bloodline [64]. These issues could lead to
omissions in the assessment of cancer family history, result-
ing in a less accurate perception of risk.
Service provision and access
Several practical issues were highlighted in relation to up-
take of cancer genetic testing. Ease of access to services
would motivate attendance for genetic testing [60]. This
could be achieved by providing services in local communi-
ties and during afternoons or weekends [35]. Physician
recommendation was also an important factor in acces-
sing services. Participants in four studies including African
Americans, Hispanics, and Chinese Australians indicated
that physician recommendation or referral would be a
motivator to testing [35, 61, 64, 67], whilst needing yet not
receiving a primary care referral would be a barrier
[60, 61, 65, 67].
“The doctor mentioned it during my last visit but he
didn’t do anything about it so I didn’t do anything.”
Hispanic female, Vadaparampil et al. [67]
As the majority of the qualitative studies took place
in the US, cost and insurance were often discussed
[35, 52, 60, 61, 63, 65–67]. Participants were unsure
whether insurance would cover the costs of testing [67]
and were unwilling or unable to pay themselves if testing
was expensive or not covered by their insurance [35]. Both
African Americans [65] and Hispanics voiced concerns
that the cost of testing would be a particular barrier
within their ethnic group due to low wages and not
having health insurance [66]. Some African American
participants who were affected by cancer indicated that
genetic testing was too important not to have due to fi-
nancial cost [60].
“I think if I had to incur the fees myself, I wouldn’t
think of going…I can’t even imagine having to pay
out of my pocket for tests.”
African American female, Ford et al. [65]
Language was identified as a barrier to using genetic
services by Hispanics in two studies [61, 66]. Participants
were concerned that poor communication, due also to
physicians’ use of complex medical language, could have
been a reason for their lack of a referral. However, some
indicated that the use of a translator, including family
members, had been helpful [61].
“But if you are let’s say Spanish and you don’t know
the terminology or you don’t know, they (the doctors)
think the person is ignorant. That’s not the case
because just because you have a language barrier
does not make you ignorant.”
Hispanic female, Sussner et al. [61]
Quality assessment
All studies scored quite highly in the quality assessment,
receiving scores of 0.75 or above (range 0.75–1.0, see
Tables 1 and 2). [Additional file 3 presents the included
studies in order of quality with comments on where the
study failed to meet the quality criteria.] The quantita-
tive studies scored well for sufficiently describing the
study objective, design, method of subject selection, and
sample characteristics. Where issues did arise, these
were mainly due to shortcomings in analytic methods,
for example failing to report sufficient estimates of vari-
ance, and having missing data that was not sufficiently
acknowledged. Six of the included quantitative studies
involved pilot research [36, 38, 46–48, 58]; however, this
did not necessarily effect the study quality score, for
example if it was stated that the analyses were explora-
tory the criteria of needing to have controlled for con-
founding was not applicable. The qualitative studies
scored highly for sufficiently describing the study object-
ive, design and context. However, none reflected on how
the personal characteristics of the researchers may have
impacted upon the analysis and results.
Discussion
The current review supports and adds to the findings of
previous work by Allford et al. [22], particularly due to
the inclusion of several studies with Hispanic partici-
pants. The results highlight that only a small proportion
of African American, Hispanic, and Asian ethnic minor-
ity groups are aware and knowledgeable about genetic
testing for cancer susceptibility, and whilst attitudes are
quite positive, concerns and negative perceptions exist.
Practical issues are also highlighted as potential barriers
to obtaining genetic counselling or testing.
Awareness of genetic testing for cancer risk varied
across the reviewed studies; however, as recently as 2014,
less than 30% of a general population sample of African
Americans and Hispanics were aware [30]. The review
also found some evidence that more White Americans are
aware of genetic testing than Asian American, African
American, and Hispanics, and this is further supported by
research which did not primarily aim to investigate ethnic
minority groups [68, 69]. Importantly, overall awareness
of genetic testing for cancer risk was low across all ethnic
groups, including White participants, highlighting that
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within the general population it is not a well-known health
service [29, 30, 32].
Ethnic minority groups’ knowledge of genetic risk of
cancer also varied across the studies reviewed, indicating
low to moderate levels of knowledge. Among samples of
participants at high risk for cancer, often less than 50%
of knowledge questions were answered correctly. Al-
though knowledge about cancer genetics may not relate
to intentions to test, individuals who lack understanding
about the hereditary nature of cancer (e.g. that BRCA
gene mutations can be passed on by male as well as fe-
male relatives) may not pursue genetic testing that is
relevant to them. Low awareness and knowledge was
also highlighted in qualitative research as a barrier to at-
tending genetic counselling or undergoing genetic test-
ing, and participants suggested a need for awareness and
educational interventions especially emphasising the im-
portance of family history of cancer. Qualitative studies
also identified several misconceptions about cancer that
could deter patients from attending cancer genetic ser-
vices. However, it is difficult to make generalisations
based on the results from qualitative research which
may only represent the views of a few individuals. Fur-
thermore, these misconceptions do not appear to be
unique to those from ethnic minority groups. For ex-
ample, Ford et al. [65] report that White women who
did not attend genetic counselling discussed the belief
that talking about breast cancer could increase their risk;
however, this misconception does not appear to have
been referred to by African American women in the
study. A study of White and Hispanic women found that
both groups held misconceptions, including that con-
suming sugar substitutes and bruising from being hit
can cause cancer; but such beliefs were found to be signifi-
cantly more prevalent in Hispanic women [70]. Similarly,
in a more recent UK study, whilst both White and South
Asian participants believed that stress causes cancer, sig-
nificantly more South Asians held this belief and a small
minority (4.3%) also believed that cancer is contagious, a
misconception that no White participants held [71].
Personal health benefits and the ability to provide in-
formation about cancer risk to the family were recog-
nised as important benefits of genetic susceptibility
testing. Family support was also discussed as a potential
motivator to testing for some Hispanics, suggesting that
interventions encouraging Hispanics to attend cancer
genetic services could benefit from involving family.
Finally, easy access to genetic services is important to fa-
cilitate uptake of genetic counselling/testing, and several
qualitative studies found that a physician recommenda-
tion was a motivator for testing. Physician education on
the hereditary basis of some cancers and the importance
of referring people with a family history of cancer for
genetic counselling is also important to ensure thorough
personal risk assessment and that all patients who could
benefit from testing are offered this.
Several negative attitudes and perceptions that might
influence uptake of genetic susceptibility testing were
found to exist among ethnic minority groups, including
reluctance to talk about cancer amongst family, concerns
about stigma, and concerns about the emotional reac-
tion of undergoing genetic testing and receiving a high
risk result. Whilst cancer stigma is not unique to ethnic
minorities [72], it is unclear to what extent such per-
ceived stigma and secrecy varies across different ethnic
groups. Research has also found that cancer stigma var-
ies in magnitude depending on the type of cancer [73].
As cancer stigma not only has negative consequences
for patients’ psychological well-being, and can also dis-
courage individuals from seeking help from healthcare
services [74], it seems important that efforts are made to
reduce stigma to encourage individuals to attend cancer
genetic services.
Other perceptions and issues identified in this review ap-
pear to be more specific to certain groups. For example,
perceptions of ‘close relatives’ among Chinese Australian
communities could hinder risk assessment based on de-
scriptions of family history of cancer, and Hispanic
women’s culture of prioritising family over their own
health could influence their behaviours relating to genetic
testing and cancer risk. These various attitudes and percep-
tions highlight the importance of identifying the barriers
and issues that are specific to different ethnic groups and
the need to tailor interventions to address them.
It is particularly important to recognise that historical
experiences of ethnic minority groups in different coun-
tries may result in varied attitudes towards healthcare and
services such as genetic testing. There is well documented
mistrust of medical research and the healthcare system
among some African Americans, influenced, for example,
by the Tuskegee Syphilis Study in which African American
males with Syphilis were misled by researchers and re-
fused treatment in order to study the progression of the
illness [75]. Practical issues, including cost and the need
for health insurance to receive testing, and concerns about
insurance discrimination as a result of testing are also
more relevant to some American ethnic minorities. The
Genetic Information Non-discrimination Act (GINA) was
signed into US law in 2008 making it illegal for health in-
surers and employers to discriminate against individuals
on the basis of genetic information and prohibiting in-
surers from requiring a person to have testing or to pro-
vide genetic information. However, the act is limited as it
does not cover disability, long-term care, or life insurance.
Furthermore, two surveys carried out in 2009/2010 in the
US, one with women at increased risk of hereditary
breast/ovarian cancer [76] and one with family physicians
[77], found that over half had not been aware of GINA
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before taking part in the survey. Considering the lack
of awareness of GINA, even amongst those that might
be expected to have an interest in it, and due to the
limitations of the act, it is perhaps unsurprising that
concerns of discrimination by insurers continues to
be cited as a limitation or barrier to genetic testing in
the US. In addition, several of the studies included in
this review were conducted before GINA was brought
into law.
Genetic testing may identify a gene change whose asso-
ciation with disease is not known, a ‘variant of unknown
significance’ (VUS). Unlike a pathogenic high risk gene
change, the association between a VUS and increased risk
of cancer is unclear, leading to issues for providers (coun-
selling, risk management and preventative care) [78] and
patients (confusion, psychological impact). It has previ-
ously been estimated that approximately 10% of Cauca-
sians undergoing BRCA genetic testing receive a VUS
result [79], with a much higher proportion in Hispanics
(9–23%) and African Americans (16–24%) [80–82]. Differ-
ent prevalence rates of VUS according to ethnic group
lead to differences in the ease of interpretation of results
between groups. That public databases of US gene testing
will have far fewer non-Whites on them than Whites con-
tributes to the problem of interpretation. Many VUS in
non-Whites will be poorly characterised compared with
Whites simply because less data is available on them. The
greater likelihood of receiving an uninformative VUS re-
sult in African ethnic groups might potentially contribute
to a lack of understanding about genetic testing or its per-
ceived benefits, but our review provides no evidence to
support this hypothesis.
The majority of the reviewed studies were conducted
in the US which limits their generalisability to other
countries, particularly in relation to levels of awareness
and knowledge. Nevertheless, lack of awareness, the
taboo of discussing cancer, and language difficulties,
have also been reported in a UK genetics service evalu-
ation [83] and a Genetics Alliance UK report involving
interviews with individuals from ethnic minorities [84].
The evaluation of a UK pilot genetic service within a
culturally diverse society by Atkin et al. [83] reports that
poor communication was a barrier for both White and
South Asian patients; however, communication issues
were most difficult for those whose first language was
not English and language support was not always viewed
positively. Furthermore, some female patients reported
that discussing breast cancer with male practitioners was
embarrassing and even felt shameful. The article high-
lights the benefit of employing multilingual, culturally
sensitive workers within the clinic [83]. In other re-
search, cancer fatalism has been found to be higher
amongst ethnic minority women in the UK than White
women, whilst cancer fear appears to vary by ethnic
group [85]. Further research into the attitudes and per-
ceptions of ethnic minority groups in the UK and other
European countries is needed in order to gain a better
understanding of specific cultural barriers to cancer sus-
ceptibility testing.
The review has a number of limitations including the
omission of intervention studies aiming to increase par-
ticipant knowledge of cancer genetics from which we
may have been able to extract baseline data. We did not
include unpublished literature and our experience of
using the quality assessment tool, specifically chosen for
its ability to assess both qualitative and quantitative
studies, indicated that it lacked a finer discriminatory
capacity. The heterogeneous nature of the measures of
awareness, knowledge, and attitudes used across various
ethnic groups and different cancer types in the quantita-
tive studies, made a meta-analysis impossible and inter-
pretation of results difficult. Furthermore, the majority
of included studies measuring knowledge and attitudes
included only at risk patients or those already with a
cancer diagnosis; therefore, results may not represent
the knowledge or attitudes of the general population of
ethnic minorities. Whilst still in the early stages of con-
ception, due to an increasing understanding of cancer
genetics and decreases in the cost of genetic testing,
population based risk stratified interventions for cancer
including genetic susceptibility testing are likely to be in-
troduced in the future. Such interventions would provide
people with information on their risk of cancer, and
screening or treatment would be recommended based
on their estimated level of risk. Before such interven-
tions become a reality it is necessary to gain an under-
standing of the attitudes of the wider population,
including those who are currently underserved such as
ethnic minority groups. Meisel et al. [86] found positive
attitudes towards population-based genetic testing and
risk stratified screening for ovarian cancer amongst a
sample of women from the UK general population.
However, just 34% of the sample interviewed were non-
White participants and cultural/ethnic differences in at-
titudes and perceptions were not discussed in detail.
Conclusions
Widening public participation amongst ethnic minority
groups in future cancer risk prediction programmes may
be enabled by culturally sensitive knowledge and aware-
ness raising interventions that decrease the stigma and
taboo of cancer. For this, further international research
is needed to provide clearer information of ethnic mi-
norities’ attitudes, and information and support needs
so that cancer risk prediction programmes are inclu-
sive and effective in the prevention and early detection
of cancer.
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